Yvon (for Derek Archila)'s questions to Kymera Therapeutics Inc (KYMR) leadership • Q1 2024
Question
Yvon, on behalf of Derek Archila, asked about Kymera's confidence in its STAT6 degrader (KT-621) showing a clear effect in atopic dermatitis (AD) within a short, 4-week study, and questioned the potential for a noisy dataset.
Answer
President and CEO Nello Mainolfi responded that the company's confidence is based on data from dupilumab, which showed compelling biomarker and clinical effects in AD at 4 weeks. He stated that Kymera's preclinical data for KT-621 has consistently shown a dupilumab-like or better effect, leading to the expectation of robust data, particularly on biomarkers, but also on clinical endpoints.